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ABSTRACT BODY:  
Introduction 
Until recently lamivudine was the only available agent to treat hepatitis B in the context of HIV 
infection in sub-Saharan Africa. Tenofovir is gradually becoming available although access remains 
far from universal. Long-term outcomes of introducing tenofovir as part of antiretroviral therapy 
(ART) in subjects previously extensively exposed to lamivudine as the sole HBV-active agent in the 
region are unknown. 
 
Methods 
We report from a prospective cohort of HIV/HBV co-infected adults attending for HIV care in Kumasi, 
Ghana, where HBsAg prevalence is 14%. HBsAg-positive subjects were invited to attend for transient 
elastography (TE) and blood sampling before the introduction of tenofovir (T0) as part of ART, and 
within 1 year (T1) and 4 years (T2) of starting tenofovir. Adherence and alcohol consumption were 
determined by a questionnaire-based interview. 
 
Results 
Overall 178 patients underwent evaluation at T0/T1, of whom 98 (55%) also attended for 
assessment at T2. Remaining patients were lost to follow up (50; 28%); had died (10; 6%); declined 
to attend (17; 10%); or were excluded due to pregnancy (2; 1%) or invalid TE (1; 1%). Of the 98 
subjects, 94 had started tenofovir-based ART and had received tenofovir for median 4 years (IQR 3.8, 
4.1), while continuing previous lamivudine (Table 1). By multivariable linear regression, female 
gender, no history of alcohol excess, and higher HBV DNA level, higher liver stiffness, and lower 
platelet count at T0/T1 were significant predictors of decreasing liver stiffness between T0/1 and T2. 
No treatment-emergent resistance mutations in HBV polymerase were observed by Sanger 
sequencing among subjects with HBV DNA>100 IU/ml at T2; one subject showed 
M204V+V173L+L180M at both T0 and T2. 
 
Conclusions 
This is the first report of the long-term impact on liver stiffness and virologic parameters of 
introducing tenofovir as part of ART in extensively lamivudine exposed HIV/HBV co-infected patients 
in sub-Saharan Africa. Significant reductions in liver stiffness and improved HBV control were 
observed at four years. 
